Harold Saul, of the Tampa office, was a delegate to the third annual Stakeholders meeting of the Kidney Health Initiative (KHI). The mission of the KHI is to advance scientific understanding of the kidney health and patient safety implications of new and existing medical products and to foster development of therapies for diseases that affect the kidney by creating a collaborative environment in which FDA and the greater nephrology community can interact to optimize evaluation of drugs, devices, biologics, and food products.